Effect of dominant follicle status at the time of retrieval on the clinical outcomes in natural cycle IVF combined with immature oocyte treatment
- PMID: 35674776
- PMCID: PMC9217702
- DOI: 10.18632/aging.204106
Effect of dominant follicle status at the time of retrieval on the clinical outcomes in natural cycle IVF combined with immature oocyte treatment
Abstract
Objective: It is commonly believed that the oocytes from small follicles are unhealthy when a dominant follicle (DF) is recruited in the ovaries, especially when the DF is ovulated. This study aims to confirm whether the presence or ovulation of DF at the time of retrieval affects the clinical outcome of the natural cycle IVF with in vitro maturation (NC-IVF/M) treatment.
Methods: Data were collected from 446 women with regular menstrual cycle and 536 retrieval cycles using NC-IVF/M treatment. The cycles were divided into three groups based on the results of the oocyte retrieval cycle. Group A covers the collection of oocytes from the DF and small follicles; Group B incorporates failed oocyte retrieval from DF and then the oocytes are retrieved only from small follicles; and Group C includes the retrieval of oocytes only from small follicles accompanied with an ovulated DF. Furthermore, Group B and C have subgroups to include whether in vivo matured oocytes were obtained from small follicles. Following aspiration of DF and small follicles, mature oocytes were inseminated on the date of retrieval by intracytoplasmic sperm injection (ICSI) and the immature oocytes were matured in vitro. If the immature oocytes were matured in vitro, they were inseminated using ICSI, and then the embryos obtained from in vivo and in vitro matured oocytes were transferred accordingly.
Results: The oocytes from DF were successfully retrieved in 445 cycles (83.0%), failed to be retrieved in 54 cycles (10.1%) and ovulated in 37 cycles (6.9%). In Group A, an average of 2.0 ± 1.7 mature oocytes were retrieved, which was significantly higher than the average of Group B, with 1.3 ± 1.3 matured oocytes and Group C, with an average of 1.1 ± 1.5 matured oocytes (P < 0.01). However, the average number of immature oocytes retrieved from each group show no difference among the three groups. There was no significant difference in maturation rates of immature oocytes, fertilization rates among the three groups. The clinical pregnancy rate per transfer cycle is 34.5%, 34.6% and 25.7% in Group A, B and C, respectively. No significant differences were observed in embryonic development and implantation capacity in Group B and C in comparison to Group A. And there was no significant difference in clinical pregnancy, implantation, live birth and miscarriage rates among the three groups. No significant differences were observed in the developmental and implantation capacity according to with or without in vivo matured oocytes were retrieved in Group B and Group C.
Conclusion: The presence or ovulation of the dominant follicle from the ovaries does not significantly influence the developmental and implantation capacity of immature oocytes retrieved from small follicles, suggesting that NC-IVF/M is a promising treatment option for women without ovarian stimulation.
Keywords: clinical outcomes; dominant follicle; embryo culture; in vitro maturation; natural cycle IVF.
Conflict of interest statement
Figures


Similar articles
-
Fertilization, embryo development, and clinical outcome of immature oocytes obtained from natural cycle in vitro fertilization.J Assist Reprod Genet. 2013 Jan;30(1):43-7. doi: 10.1007/s10815-012-9889-5. Epub 2012 Nov 21. J Assist Reprod Genet. 2013. PMID: 23179385 Free PMC article.
-
Analysis of IVF/ICSI-FET Outcomes in Women With Advanced Endometriosis: Influence on Ovarian Response and Oocyte Competence.Front Endocrinol (Lausanne). 2020 Jul 17;11:427. doi: 10.3389/fendo.2020.00427. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32765424 Free PMC article.
-
Comparison of pregnancy outcomes in natural cycle IVF/M treatment with or without mature oocytes retrieved at time of egg collection.Syst Biol Reprod Med. 2012 Jun;58(3):154-9. doi: 10.3109/19396368.2012.655403. Epub 2012 Feb 3. Syst Biol Reprod Med. 2012. PMID: 22300260
-
State of the art in in-vitro oocyte maturation.Curr Opin Obstet Gynecol. 2004 Jun;16(3):211-9. doi: 10.1097/00001703-200406000-00003. Curr Opin Obstet Gynecol. 2004. PMID: 15129050 Review.
-
Optimization of ovum pick-up-in vitro fertilization and in vitro growth of immature oocytes in ruminants.J Reprod Dev. 2025 Feb 5;71(1):1-9. doi: 10.1262/jrd.2024-091. Epub 2024 Dec 22. J Reprod Dev. 2025. PMID: 39710384 Free PMC article. Review.
Cited by
-
In vitro maturation (IVM) of human immature oocytes: is it still relevant?Reprod Biol Endocrinol. 2023 Nov 22;21(1):110. doi: 10.1186/s12958-023-01162-x. Reprod Biol Endocrinol. 2023. PMID: 37993914 Free PMC article. Review.
-
Current status and hotspots of in vitro oocyte maturation: a bibliometric study of the past two decades.J Assist Reprod Genet. 2025 Feb;42(2):459-472. doi: 10.1007/s10815-024-03272-w. Epub 2024 Sep 25. J Assist Reprod Genet. 2025. PMID: 39317914 Review.
-
IVM of human immature oocytes for infertility treatment and fertility preservation.Reprod Med Biol. 2023 Jul 11;22(1):e12524. doi: 10.1002/rmb2.12524. eCollection 2023 Jan-Dec. Reprod Med Biol. 2023. PMID: 37441160 Free PMC article. Review.
-
Effects of different sperm sources on the clinical outcomes of in vitro oocyte maturation cycles combined with intracytoplasmic sperm injection.Front Endocrinol (Lausanne). 2023 Feb 20;14:1115210. doi: 10.3389/fendo.2023.1115210. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36891059 Free PMC article.
References
-
- Jones HW Jr, Jones GS, Andrews MC, Acosta A, Bundren C, Garcia J, Sandow B, Veeck L, Wilkes C, Witmyer J, Wortham JE, Wright G. The program for in vitro fertilization at Norfolk. Fertil Steril. 1982; 38:14–21. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous